Guggenheim Maintains Buy on Biogen, Raises Price Target to $260

Benzinga Newsdesk www.benzinga.com Positive 76.4%

Neg 0% Neu 0% Pos 76.4%

Guggenheim analyst Yatin Suneja maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $246 to $260.